The Effects of a Novel Curcumin Derivative Loaded Long-Circulating Solid Lipid Nanoparticle on the MHCC-97H Liver Cancer Cells and Pharmacokinetic Behavior

Abstract

Purpose The objective of this study was to develop long-circulating solid lipid nanoparticles (LSLN) containing a novel curcumin (CU) derivative (CU1), to improve CU1ʹs pharmacokinetic behavior and its anti-cancer effects in MHCC-97H liver cancer cells. Methods LSLN loaded with CU1 (CU1-LSLN) was optimized and characterized. The cell biological properties and the anti-cancer mechanism of CU1-LSLN on MHCC-97H cells were evaluated by MTT, flow cytometry, Transwell, and Western blot. CU1-LSLN was further evaluated for pharmacokinetic behavior, biodistribution, and liver toxicity in SD rats. Results The optimized CU1-LSLN formulation showed the ideal particle size (PS), polydispersity index (PDI), zeta potential (ZP), encapsulation efficiency (EE%), and drug loading (DL%) of 122.10 ± 6.63 nm, 0.19 ± 0.02, −36.30 ± 1.25 mV, 94.98 ± 0.90% and 4.53 ± 0.69%, respectively. X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), and Fourier transform infrared spectrometry (FTIR) indicated that CU1 was well encapsulated by LSLN and existed in amorphous form. Storage stability of CU1-LSLN was up to 180 days with a sustained-release of drug over 96 h. The uptake efficiency of CU1-LSLN to MHCC-97H cells was 3.24 and 2.98 times higher than that of CU and CU1 after treatment for 3 h, which helped to enhance the inhibitive effect of CU1-LSLN on the proliferation, migration, and invasion potential of MHCC-97H cells and increased its ability to promote apoptosis. Meanwhile, the expression levels of NF-κB, COX-2, MMP-2, MMP-9, and uPA decreased significantly. In vivo, CU1-LSLN prolonged the retention time of the drug, the area under the curve (AUC) increased significantly (CU: 69.9-fold, CU1: 85.9-fold), and no significant liver toxicity was observed. Conclusion CU1-LSLN is a novel preparation with great potential for treating liver cancer.

Self-Augmented Reactive Oxygen Species-Responsive Nanoformulation with Efficient Curcumin Delivery for Inhibiting Triple-Negative Breast Cancer Cell Growth and Migration

“…In order to evaluate the antitumor effects, 4T1 bearing mice were randomly divided into 5 treatment groups and the dose of CUR was 10 mg/kg. , The administration was performed every 2 days, and mice received five treatments. Meanwhile, the diameter of tumor and body weigh were recorded, and tumor volume was calculated as 0.5 a × b 2 , where “ a ” was the longest diameter and “ b ” was the shortest one.…”

Innovative Delivery Systems for Curcumin: Exploring Nanosized and Conventional Formulations

“…Nanoformulation circumvents this limitation by dispersing curcumin molecules within the aqueous core or lipid bilayers of nanoparticles, thereby increasing their dispersibility and dissolution rate. In liposomal formulations, curcumin is encapsulated within the aqueous core or incorporated into the lipid bilayers [62][63][64], and can fuse with cellular membranes, facilitating the direct uptake of curcumin by cells [65,66]. Also, surface modifications of liposomes with ligands or targeting moieties further improve their specificity and efficacy in delivering curcumin to specific tissues or cells [36].…”

Advances of Nanotechnology in the Diagnosis and Treatment of Hepatocellular Carcinoma

“…Meanwhile, the expression of NF-kB, COX-2, MMP-2, MMP-9, and uPA decreased considerably. Because of LSLN's distinct metabolic activity, CU1-LSLN has a significantly higher relative bioavailability and improved pharmacokinetic behavior [90].…”